Evidence map›Paper›PMID 31792071›Full record

ArticleMolecular & cellular proteomics : MCP2020

Profiling the Surfaceome Identifies Therapeutic Targets for Cells with Hyperactive mTORC1 Signaling.

Junnian Wei, Kevin Leung, Charles Truillet, Davide Ruggero, James A Wells, Michael J Evans

Open access · hybridAbstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Junnian WeiDepartment of Radiology and Biomedical Imaging, University of California San Francisco 505 Parnassus Ave, San Francisco California 94143.
Kevin LeungDepartment of Pharmaceutical Chemistry, University of California San Francisco, 505 Parnassus Ave, San Francisco California 94143.
Charles TruilletImagerie Moleculaire In Vivo, INSERM, CEA, Univ. Paris Sud, CNRS, Universite Paris Saclay, CEA-Service Hospitalier Frederic Joliot, Orsay France, 94100.
Davide RuggeroDepartment of Urology, University of California San Francisco, 505 Parnassus Ave, San Francisco California 94143; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 505 Parnassus Ave, San Francisco California 94143.
James A WellsDepartment of Pharmaceutical Chemistry, University of California San Francisco, 505 Parnassus Ave, San Francisco California 94143; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 505 Parnassus Ave, San Francisco California 94143. Electronic address: jim.wells@ucsf.edu.
Michael J EvansDepartment of Radiology and Biomedical Imaging, University of California San Francisco 505 Parnassus Ave, San Francisco California 94143; Department of Pharmaceutical Chemistry, University of California San Francisco, 505 Parnassus Ave, San Francisco California 94143; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 505 Parnassus Ave, San Francisco California 94143. Electronic address: michael.evans@ucsf.edu.
University of California, San Francisco · USCentre National de la Recherche Scientifique · FR

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Leigh Clarke · 1999 to 2026
$209.7M
Renewable antibodies to secreted proteins and single and multi-pass cell surfaceP41CA196276 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIK, CHARLES SCOTT · 2014 to 2018
$5.8M
Surfaceomic technologies and antibodies to probe cell surface proteomes and their interactomes at unprecedented small scale and high-resolutionR35GM122451 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAMES A WELLS · 2017 to 2026
$5.3M
NCI NIH HHS P30 CA082103NCI NIH HHS P41 CA196276NIGMS NIH HHS R35 GM122451
6 · The paper itself

Abstract

Aberrantly high mTORC1 signaling is a known driver of many cancers and human disorders, yet pharmacological inhibition of mTORC1 rarely confers durable clinical responses. To explore alternative therapeutic strategies, herein we conducted a proteomics survey to identify cell surface proteins upregulated by mTORC1. A comparison of the surfaceome from

Indexed as

AnimalsCD13 AntigensCell LineHumansMaleMechanistic Target of Rapamycin Complex 1Membrane ProteinsMiceMice, NudeNeoplasmsNeprilysinProteomicsRNA, Small InterferingSignal TransductionTuberous Sclerosis Complex 1 ProteinTuberous Sclerosis Complex 2 ProteinCD13 AntigensMechanistic Target of Rapamycin Complex 1Membrane ProteinsNeprilysinRNA, Small InterferingTsc1 protein, mouseTsc2 protein, mouseTuberous Sclerosis Complex 1 ProteinTuberous Sclerosis Complex 2 Proteincancer biologycancer therapeuticscell biologydrug targetsmembranesmouse modelsSILAC

Identifiers

PMID31792071
PMCPMC7000124
OpenAlexW2993833902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.